Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. filed a Current Report on Form 8-K regarding a material definitive agreement entered into on July 2, 2021. The company is developing vonoprazan fumarate tablets for commercial use. The report was signed on July 8, 2021; it does not present results for a fiscal reporting period.
Material Agreement and Key Terms
- Phathom entered into a Commercial Supply Agreement with Catalent Pharma Solutions, LLC.
- Catalent will supply commercial quantities of vonoprazan fumarate finished tablets, and Phathom will purchase the tablets at an agreed price per unit.
- The unit price may be adjusted annually for increases in Catalent’s costs.
- Phathom must purchase a specified percentage of its finished-tablet requirements from Catalent. This percentage may be adjusted after the third anniversary of the Commencement Date.
- The initial term is five years from the Commencement Date, defined as the first day of the calendar quarter in which Catalent is scheduled to deliver initial commercial-sale tablets, excluding validation batches.
- The agreement automatically renews for additional two-year periods unless either party provides at least 24 months’ prior written notice of termination.
- Either party may terminate following an uncured material breach after required notice and a specified remediation period.
- The agreement includes customary provisions covering forecasts, delivery, payment, transportation, intellectual property, confidentiality, warranties, and indemnification.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, pricing amounts, purchase commitments, or other quantitative financial metrics.
Changes, Outlook, and Risks
- The agreement establishes a commercial manufacturing and supply relationship for Phathom’s finished tablets and may support future commercialization activities.
- Financial obligations may vary with the agreed unit price, annual cost-based adjustments, required purchase percentage, demand, and delivery requirements.
- The filing does not provide management guidance, commercialization timing, volume forecasts, or an assessment of the agreement’s expected financial impact.
- Certain agreement provisions will be redacted for confidentiality, and the complete agreement will be filed as an exhibit to Phathom’s Form 10-Q for the quarter ended June 30, 2021.
Investor Verification Points
- Verify the Commencement Date and the resulting initial term and renewal dates.
- Review the redacted Supply Agreement for unit pricing, minimum purchase or volume obligations, required purchase percentages, forecasts, and capacity commitments.
- Assess the extent of annual price-adjustment rights and potential cost exposure.
- Review delivery, quality, supply interruption, indemnification, and termination provisions.
- Compare subsequent filings for the agreement’s financial impact, manufacturing progress, regulatory status, and commercialization plans.